NK95806, a newly synthesized microtubule-disrupting agent that suppresses collagen-induced arthritis in mice

International Immunopharmacology

Volumn 4, Issue 12, 2004, Pages 1437-1443

  Morohashi, Hirohisa ^a   Abe, Fuminori ^a   Saiga, Kan ^a   Toyoda, Eriko ^a   Ichimura, Eiji ^a   Nishikawa, Kiyohiro ^a  

^a NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Anti rheumatic drug; Collagen induced arthritis; Methotrexate; Microtubule polymerization inhibitor; NK95806

Indexed keywords

ANTIRHEUMATIC AGENT; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; METHOTREXATE; MICROTUBULE PROTEIN; N [2 (4 METHOXYBENZENESULFONAMIDE)PHENYL] 3,5 DIMETHYL 4 ISOXAZOLE CARBOXAMIDE; NK 95806; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SYNTHESIS; GRANULOMATOSIS; HISTOPATHOLOGY; MALE; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; ISOXAZOLES; JOINTS; LOWER EXTREMITY; MALE; MICE; MICE, INBRED STRAINS; MICROTUBULES; SULFONAMIDES;

EID: 4444249919     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.06.013     Document Type: Article

References (25)

1. L.E. Theil RaANK-L and RANK: T cells, boneloss, and mammalian evolution Annu. Rev. Immunol. 20 2002 795 823
2. G.S. Firestein, and A.M. Manning Signal transduction and transcription factors in rheumatic disease Arthritis Rheuma 42 1999 609 621
3. P. Piascik New antibody approved for treatment of rheumatoid arthritis J. Am. Pharm. Assoc. 43 2003 327 328
4. L. Kuritzky, and A. Weaver Advances in rheumatology: coxibs and beyond J. Pain Symptom Manage. 25 2003 S6 S20
5. M. Osiri, B. Shea, V. Robinson, M. Suarez-Almazor, V. Strand, and P. Tugwell Leflunomide for treating rheumatoid arthritis Cochrane Database Syst. Rev. 1 2003 CD002047
6. A. Larsen, I. Petersson, and B. Svensson Podophyllum derivatives (CPH 82) compared with placebo in the treatment of rheumatoid arthritis Br. J. Rheumatol. 28 1989 124 127
7. A.L. Arsenault, S. Lhotak, W.L. Hunter, M.L. Banquerigo, and E. Brahn Taxol involution of collagen-induced arthritis: ultra-structural correlation with the inhibition of synovitis and neovascularization Clin. Immunol. Immunopathol. 86 1998 280 289
8. F.D. Malkinson Colchicine, new uses of an old drug Arch. Dermatol. 118 1982 453 457
9. M.L. Shelansky, F. Gaskin, and C.R. Cantor Microtubule assembly in the absence of added nucleotides Proc. Acad. Sci. U. S. A. 70 1973 765 770
10. K. Nemoto, T. Mae, F. Abe, and T. Takeuchi Successful treatment with a novel immunosuppressive agent, deoxyspergualin, in type II collagen-induced arthritis in mice Ann. N.Y. Acad. Sci. 685 1993 148 154
11. H. Mori, R. Kitazawa, S. Mizuki, M. Nose, S. Maeda, and S. Kitazawa RANK ligand, RANK and OPG expression in type II collagen induced arthritis mouse Histochem. Cell Biol. 117 2002 283 292
12. D.G. Stupack, C.M. Storgard, and D.A. Cheresh A role for angiogenesis in rheumatoid arthritis Braz. J. Med. Biol. Res. 32 2000 573 578
13. H.K. Choi, M.A. Hernan, J.D. Seeger, J.M. Robins, and F. Wolfe Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study Lancet 359 2002 1173 1177
14. A.H. Ding, F. Porteu, E. Sanchez, and C.F. Nathan Down regulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents J. Exp. Med. 171 1990 715 727
15. K. Kobayashi, N. Takahashi, E. Jimi, N. Udagawa, N. Takami, and S. Kotake Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction J. Exp. Med. 191 2000 275 286
16. S. Niida, M. Kaku, H. Amano, H. Yoshida, H. Kataoka, and S. Nishikawa Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption J. Exp. Med. 190 1999 293 298
17. A.L. Arsenault, S. Lhotak, W.L. Hunter, M.L. Strand, and E. Brah Taxol involution of collagen-induced arthritis: ultra-structural correlation with the inhibition of synovitis and neovascularization Clin. Immunol. Immunopathol. 86 1998 280 286
18. D. Belotti, V. Vergani, T. Drudis, P. Borsotti, M.R. Pitelli, and G. Viale The microtubule-affecting drug pacritaxel has antiangiogenic activity Clin. Cancer Res. 2 1996 1843 1849
19. S.L. Mooberry, R.M. Leal, T.L. Tinley, H. Luesch, R.E. Moore, V. Strand, and T.H. Corbett The molecule pharmacology of symplotatin 1: a new antimitotic dolastatin 10 analog Int. J. Cancer 104 2003 512 521
20. K. Hori, S. Saito, and K. Kubota A novel combretastatin A-4 derivative, AC7700, strongly stanches tumor blood flow and inhibits growth of tumours developing in various tissues and organs Br. J. Cancer 86 2002 1604 1614
21. B.N. Cronstein, Y. Molad, J. Reibman, E. Balakhane, R.I. Levin, and G. Weissmann Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils J. Clin. Invest. 96 1995 994 1002
22. B.P. Eliceiri, and D.A. Cheresh The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development J. Clin. Invest. 103 1999 1227 1236
23. S. Kim, K. Bell, S.A. Mousa, and J.A. Varner Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin Am. J. Pathol. 156 2000 1345 1362
24. D.G. Stupack, C.M. Storgard, and D.A. Cheresh A role for angiogenesis in rheumatoid arthritis Braz. J. Med. Biol. Res. 32 2000 573 581
25. C.P. Carron, D.M. Meyer, V.W. Engleman, J.G. Rico, P.G. Ruminski, and R.L. Ornberg Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone J. Endocrinol. 165 2000 587 598